republic-os/legislation/us/states/ca/20152016/ab-1668.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	Investigational drugs, biological products, and devices.	Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the United States Food and Drug Administration (FDA) . Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.	us/states/ca	California Legislature	20152016	AB 1668	California AB 1668 (20152016)	bill	Investigational drugs biological products and devices.	enacted	Calderon	6	24	10	2016-01-15	2016-09-27	openstates	ocd-bill/2d82af8c-6ec5-47b8-949d-8e9fec1ea823	http://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201520160AB1668	8926919f59b9fc0c2e1551d257bf454eff80d7a407f086ee5e10d8c991e7d6dd	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-ca

California AB 1668 (20152016) — Investigational drugs, biological products, and devices.

Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the United States Food and Drug Administration (FDA) . Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. 01/15/16 - Introduced (filed) — source
2. 03/07/16 - Amended Assembly (committee substitute) — source
3. 08/15/16 - Amended Senate (committee substitute) — source
4. 09/27/16 - Chaptered (committee substitute) — source
5. AB1668 (committee substitute) — source
6. 08/25/16 - Enrolled (enrolled) — source

Votes

• AB 1668 CALDERON Concurrence in Senate Amendments — 77–2 (pass) · lower
• Do pass, but first be re-referred to the Committee on [Appropriations] — 9–0 (pass) · upper
• 3rd Reading AB1668 Calderon By Stone — 38–0 (pass) · upper
• Do pass. — 20–0 (pass) · lower
• Do pass as amended — 7–0 (pass) · upper
• AB 1668 CALDERON Assembly Third Reading — 77–2 (pass) · lower
• Do pass and be re-referred to the Committee on [Business and Professions] — 18–0 (pass) · lower
• Do pass, but first be re-referred to the Committee on [Business, Professions and Economic Development] — 9–0 (pass) · upper
• Do pass and be re-referred to the Committee on [Appropriations] — 14–0 (pass) · lower
• Placed on suspense file — 7–0 (pass) · upper

Sponsors

• Calderon — primary (person)
• Alejo — coauthor (person)
• Allen — coauthor (person)
• Bonta — coauthor (person)
• Brown — coauthor (person)
• Campos — coauthor (person)
• Chu — coauthor (person)
• Dababneh — coauthor (person)
• Daly — coauthor (person)
• Frazier — coauthor (person)
• Galgiani — coauthor (person)
• Gatto — coauthor (person)
• Gipson — coauthor (person)
• Gonzalez — coauthor (person)
• Gray — coauthor (person)
• Hadley — coauthor (person)
• Jones-Sawyer — coauthor (person)
• Lackey — coauthor (person)
• Linder — coauthor (person)
• Low — coauthor (person)
• Mark Stone — coauthor (person)
• McCarty — coauthor (person)
• Medina — coauthor (person)
• O'Donnell — coauthor (person)
• Obernolte — coauthor (person)
• Olsen — coauthor (person)
• Rendon — coauthor (person)
• Rodriguez — coauthor (person)
• Roger Hernández — coauthor (person)
• Runner — coauthor (person)
• Salas — coauthor (person)
• Stone — coauthor (person)
• Waldron — coauthor (person)
• Williams — coauthor (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2016-01-15 Read first time. To print. reading-1
• 2016-01-19 From printer. May be heard in committee February 18.
• 2016-02-04 Referred to Coms. on HEALTH and B. & P. referral-committee
• 2016-03-07 From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. reading-2, amendment-introduction, amendment-passage, reading-1
• 2016-03-08 Re-referred to Com. on HEALTH. referral-committee
• 2016-03-16 From committee: Do pass and re-refer to Com. on B. & P. (Ayes 18. Noes 0.) (March 15). Re-referred to Com. on B. & P. referral-committee, committee-passage-favorable, committee-passage
• 2016-03-29 From committee: Do pass and re-refer to Com. on APPR. (Ayes 14. Noes 0.) (March 29). Re-referred to Com. on APPR. referral-committee, committee-passage-favorable, committee-passage
• 2016-04-06 In committee: Set, first hearing. Referred to APPR. suspense file. referral-committee
• 2016-05-27 From committee: Do pass. (Ayes 20. Noes 0.) (May 27). committee-passage-favorable, committee-passage
• 2016-05-27 Read second time. Ordered to third reading. reading-2, reading-1
• 2016-05-31 Read third time. Passed. Ordered to the Senate. (Ayes 77. Noes 2. Page 5020.) reading-3, passage, reading-1
• 2016-06-01 In Senate. Read first time. To Com. on RLS. for assignment. reading-1
• 2016-06-09 Referred to Coms. on HEALTH and B., P. & E.D. referral-committee
• 2016-06-23 From committee: Do pass and re-refer to Com. on B., P. & E.D. (Ayes 9. Noes 0.) (June 22). Re-referred to Com. on B., P. & E.D. referral-committee, committee-passage-favorable, committee-passage
• 2016-06-28 From committee: Do pass and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (June 27). Re-referred to Com. on APPR. referral-committee, committee-passage-favorable, committee-passage
• 2016-08-01 In committee: Referred to APPR. suspense file. referral-committee
• 2016-08-11 From committee: Amend, and do pass as amended. (Ayes 7. Noes 0.) (August 11). amendment-introduction, committee-passage, amendment-passage
• 2016-08-15 Read second time and amended. Ordered to third reading. amendment-passage, reading-2, reading-1
• 2016-08-18 Read third time. Passed. Ordered to the Assembly. (Ayes 38. Noes 0. Page 5117.). reading-3, passage, reading-1
• 2016-08-19 In Assembly. Concurrence in Senate amendments pending. May be considered on or after August 21 pursuant to Assembly Rule 77.
• 2016-08-23 Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 77. Noes 2. Page 6157.). committee-passage-favorable, amendment-passage
• 2016-08-30 Enrolled and presented to the Governor at 4 p.m.
• 2016-09-27 Approved by the Governor. executive-signature
• 2016-09-27 Chaptered by Secretary of State - Chapter 684, Statutes of 2016.

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/2d82af8c-6ec5-47b8-949d-8e9fec1ea823. Confidence: reported (aggregated from official California legislature records).